bluebird bio
Somerville, Massachusetts, United States · Biotechnology, Health Care, Therapeutics
bluebird bio is a commercial-stage biotherapeutics company focused on developing and delivering gene therapies for severe genetic diseases. With more than a decade of scientific leadership in gene therapy and three FDA-approved therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy, the company is committed to ensuring access, reliability, and patient-centered care.
Key facts
- Headquarters
- Somerville, Massachusetts, United States
- Employees
- 449
- Industries
- Biotechnology, Health Care, Therapeutics
- Website
- http://www.bluebirdbio.com/
- Company page
Recent activity at bluebird bio
- : bluebird bio Appoints Brian Riley as President and Chief Technical Officer
- : Bluebird Bio to be Acquired by Carlyle and SK Capital Partners to Scale Up Gene Therapy Deliveries (date Fundz recorded it)
- : bluebird bio, Inc. presents new long-term data on gene therapy for sickle cell disease and beta-thalassemia at the 66th ASH Annual Meeting.
- : O. James Sterling Appointed as Chief Financial Officer of bluebird bio, Inc.
- : Bluebird Bio secures up to $175M in debt financing with Hercules Capital to extend its cash runway beyond the next 24 months.
- : bluebird bio, Inc. secures up to $175 million debt financing with Hercules Capital for commercial launches of FDA approved gene therapies.
- : bluebird bio, Inc.
- : Bluebird Bio Secures $75 Million In Private Placement Equity Financing
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
bluebird bio funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2024 | Debt Financing | $175.0M |
| Mar 2024 | Debt Financing | $175.0M |
| Sep 2021 | Venture | $75.0M |
| Sep 2021 | Post-IPO Equity | $75.0M |
Leadership
- Tom Klima, Director
- Adrian Chaisson, Chief of Staff
- Joanne Lager, Chief Medical Officer
- Brian Riley, President
- Andrew Obenshain, Chief Executive Officer
Verified email and direct lines for bluebird bio’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
bluebird bio files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
bluebird bio in the news
- U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma - Bristol Myers Squibb (Mar 26, 2021)
- Potential blockbusters make a splash on market entry - Clarivate (Jun 13, 2019)
Companies similar to bluebird bio
- BioCryst Pharmaceuticals · Biotechnology, Health Care, Therapeutics
- Arvinas · Biotechnology, Health Care, Therapeutics
- Debiopharm · Biotechnology, Health Care, Therapeutics
- Cyllene · Biotechnology, Health Care, Therapeutics
- Veristat · Biotechnology, Health Care, Therapeutics
About bluebird bio: questions and answers
What does bluebird bio do?
bluebird bio is a commercial-stage biotherapeutics company focused on developing and delivering gene therapies for severe genetic diseases. With more than a decade of scientific leadership in gene therapy and three FDA-approved therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy, the company is committed to ensuring access, reliability, and patient-centered care.
Where is bluebird bio headquartered?
bluebird bio is headquartered in Somerville, Massachusetts, United States.
How many employees does bluebird bio have?
bluebird bio has about 449 employees.
Has bluebird bio raised funding?
Yes. Fundz has recorded 4 funding events for bluebird bio. The most recent, Debt Financing of $175.0M, was in Mar 2024.
Who leads bluebird bio?
Brian Riley is a President at bluebird bio.
What is the latest news on bluebird bio?
On Jul 2, 2025, bluebird bio Appoints Brian Riley as President and Chief Technical Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy